[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100543232":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":29,"responsibleParty":95,"collaborators":97,"id":101,"slug":102,"hasResults":103,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":10,"eligibilityCriteria":107,"healthyVolunteers":103,"sex":108,"minAge":109,"maxAge":10,"enrollmentInfo":110,"targetDuration":10,"studyType":113,"phases":10,"briefSummary":114,"conditions":115,"keywords":10,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":127},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational",null,"Patients undergo blood sample collection and have their medical records reviewed on study. Patients may also optionally undergo ECG on study.",[13],"Other: Non-Interventional Study",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Non-Interventional Study","Non-interventional study",[9],[20],{"name":21,"affiliation":5,"role":22},"Nadine Norton, PhD","PRINCIPAL_INVESTIGATOR",[24],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Clinical Trials Referral Office","CONTACT","855-776-0015","mayocliniccancerstudies@mayo.edu",[30,52,69,84],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Mayo Clinic in Arizona","RECRUITING","Scottsdale","Arizona","85259","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-111.89903,33.50921,{"lat":42,"lon":41},[45,46,50],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},{"name":47,"role":26,"phone":48,"phoneExt":10,"email":49},"Myrah Manuel","480-574-3157","Manuel.Myrah@mayo.edu",{"name":51,"role":22,"phone":10,"phoneExt":10,"email":10},"Lida A. Mina, MD",{"facility":53,"status":32,"city":54,"state":55,"zip":56,"country":36,"countryCode":37,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"Mayo Clinic in Florida","Jacksonville","Florida","32224-9980",{"type":39,"coordinates":58},[59,60],-81.65565,30.33218,{"lat":60,"lon":59},[63,64,68],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},{"name":65,"role":26,"phone":66,"phoneExt":10,"email":67},"Pamela Williamson","904-953-4694","Williamson.Pamela@mayo.edu",{"name":21,"role":22,"phone":10,"phoneExt":10,"email":10},{"facility":70,"status":32,"city":71,"state":55,"zip":72,"country":36,"countryCode":37,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Moffitt Cancer Center","Tampa","33612",{"type":39,"coordinates":74},[75,76],-82.45843,27.94752,{"lat":76,"lon":75},[79,83],{"name":80,"role":26,"phone":81,"phoneExt":10,"email":82},"Aixa Soyano, MD","813-745-8268","aixa.soyano@Moffitt.org",{"name":80,"role":22,"phone":10,"phoneExt":10,"email":10},{"facility":85,"status":86,"city":87,"state":88,"zip":89,"country":36,"countryCode":37,"cosmosGeoPoint":90,"geoPoint":94,"contacts":10},"Mayo Clinic in Rochester","SUSPENDED","Rochester","Minnesota","55905",{"type":39,"coordinates":91},[92,93],-92.4699,44.02163,{"lat":93,"lon":92},{"type":96,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[98],{"name":99,"class":100},"National Heart, Lung, and Blood Institute (NHLBI)","NIH","100543232","biomarkers-to-predict-cancer-therapy-related-cardiotoxicity-100543232",false,"NCT06353191","Biomarkers to Predict Cancer Therapy-related Cardiotoxicity","Biomarkers to Predict Cancer Therapy-Related Cardiotoxicity","Inclusion Criteria:\n\n* 18 years of age or older\n* Treated for any malignancy with any type of chemotherapy including oral, parenteral therapy and immunotherapy\n* One of the following:\n\n  * Diagnosed with cardiotoxicity defined as; cardiomyopathy, symptomatic heart failure, asymptomatic reduced systolic function, acute coronary syndrome, myocardial infarction, critical limb ischemia, cardiac arrhythmias or myocarditis possibly related to prior cancer treatment\n  * Completed chemotherapy with no cardiotoxicity at least two years post treatment\n  * Patients with cancer who will be initiating systemic therapy with potentially cardiotoxic medications. This will include chemotherapy, immunotherapy, targeted therapy that have been associated with cardiac toxicity\n* An understanding of the protocol and its requirements, risks, and discomforts\n* The ability and willingness to sign an informed consent\n\nExclusion Criteria:\n\n\\- Inability on the part of the patient to understand the informed consent or be compliant with the protocol","ALL","18 Years",{"count":111,"type":112},693,"ESTIMATED","OBSERVATIONAL","This study evaluates why some cancer patients but not others experience changes in heart function following treatment with chemotherapy.",[116,117],"Hematopoietic and Lymphatic System Neoplasm","Malignant Solid Neoplasm","2026-08-14",{"date":120,"type":121},"2026-08-18","ACTUAL",{"date":123,"type":121},"2019-05-03",{"date":125,"type":112},"2031-12-31",{"name":5,"class":6},4]